Loading...
Market
Halozyme's Acquisition of Evotec at €11 per Share by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Halozyme and Evotec, or financial news outlets like Bloomberg or Reuters
Story
Halozyme Proposes €2 Billion Takeover of Evotec at €11 Per Share, 27% Premium
Nov 14, 2024, 09:30 PM
Halozyme Therapeutics is reportedly exploring a takeover of the German drugmaker Evotec, with a proposed acquisition valued at approximately €2 billion ($2.1 billion). The offer includes a cash payment of €11 per share, representing a 27% premium over Evotec's last closing price. This potential acquisition aims to enhance Halozyme's drug discovery and development portfolio. The interest from Halozyme comes as Evotec has garnered attention in the biotechnology sector, with various reports confirming the ongoing discussions between the two companies.
View original story
Similar markets
Takeover completed • 25%
Takeover offer made but not completed • 25%
No takeover offer made • 25%
Triton sells its stake • 25%
Increase by 0-5% • 25%
Increase by 5-10% • 25%
Increase by 10-15% • 25%
Increase by more than 15% • 25%
Outperforms DAX by more than 10% • 25%
Outperforms DAX by up to 10% • 25%
Performs similar to DAX • 25%
Underperforms DAX • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Yes • 50%
No • 50%
